BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liebowitz MR, Careri J, Blatt K, Draine A, Morita J, Moran M, Hanover R. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depress Anxiety 2017;34:1164-72. [DOI: 10.1002/da.22702] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Cao B, Park C, Rosenblat JD, Chen Y, Iacobucci M, Subramaniapillai M, Mansur RB, Zuckerman H, Lee Y, Mcintyre RS. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. J Psychopharmacol 2019;33:1388-94. [DOI: 10.1177/0269881119874485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Ballanger B, Bath KG, Mandairon N. Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging. Neurobiol Aging 2019;82:18-29. [PMID: 31377537 DOI: 10.1016/j.neurobiolaging.2019.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Chokka P, Ge H, Bougie J, Ettrup A, Clerzius G. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study. Ther Adv Psychopharmacol 2021;11:20451253211013148. [PMID: 34025982 DOI: 10.1177/20451253211013148] [Reference Citation Analysis]
4 Rozen N, Aderka IM. The effect of depression on treatment outcome in social anxiety disorder: an individual-level meta-analysis. Cogn Behav Ther 2021;:1-32. [PMID: 34617874 DOI: 10.1080/16506073.2021.1966089] [Reference Citation Analysis]
5 He H, Xiang Y, Gao F, Bai L, Gao F, Fan Y, Lyu J, Ma X. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research 2019;118:21-30. [DOI: 10.1016/j.jpsychires.2019.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
6 Zhang X, Luo Q, Wang S, Qiu L, Pan N, Kuang W, Lui S, Huang X, Yang X, Kemp GJ, Gong Q. Dissociations in cortical thickness and surface area in non-comorbid never-treated patients with social anxiety disorder. EBioMedicine 2020;58:102910. [PMID: 32739867 DOI: 10.1016/j.ebiom.2020.102910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
8 Zimmerman M, Kerr S, Kiefer R, Balling C, Dalrymple K. What is anxious depression? Overlap and agreement between different definitions. J Psychiatr Res 2019;109:133-8. [PMID: 30530208 DOI: 10.1016/j.jpsychires.2018.11.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. Ther Adv Psychopharmacol 2021;11:20451253211034320. [PMID: 34497709 DOI: 10.1177/20451253211034320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. Int Clin Psychopharmacol 2020;35:305-12. [PMID: 32784346 DOI: 10.1097/YIC.0000000000000326] [Reference Citation Analysis]
11 Santos-Casado M, Guisado-Gil AB, Santos-Ramos B. Systematic review of gender bias in vortioxetine clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 2021;108:110088. [PMID: 32890693 DOI: 10.1016/j.pnpbp.2020.110088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Rozen N, Aderka IM. Do depressive symptoms affect the outcome of treatments for SAD? A meta analysis of randomized controlled trials. Clin Psychol Rev 2020;80:101874. [PMID: 32653699 DOI: 10.1016/j.cpr.2020.101874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Koyuncu A, İnce E, Ertekin E, Tükel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs Context 2019;8:212573. [PMID: 30988687 DOI: 10.7573/dic.212573] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]